The transfusion service plays a critical role in the management of perinatal patients. This interactive session will engage the audience and speakers in an active discussion on approaches for testing and management of this patient population. Topics presented are those identified as controversial or for which there is no unified approach and include:
The timing and frequency of type and screens during pregnancy, and the need for type and screen with crossmatch at delivery.
The indications to perform molecular tests i.e., maternal RHD genotyping to distinguish weak D from partial D and fetal RHD genotyping using cell-free DNA to make decisions regarding the need for monitoring and Rh immune globulin administration.
Guidance about antibody critical titer thresholds and the appropriate management once critical titer is reached.
Suggestions regarding which cord blood tests should and should not be performed to diagnose and assess future risk of hemolytic disease of the fetus and newborn.
To view Spanish or English subtitles, click the "CC" box in the video player. Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Design a strategy for determining the frequency and interpretation of antibody titers and when referral to a high risk fetomaternal specialist is required.
Identify which molecular tests are available and when they may be beneficial in the management of obstetric patients at risk for hemolytic disease of the fetus and newborn.
Judge when and which tests performed on cord blood samples may benefit patient outcomes.
Identify gaps where protocols and guidelines for the management of obstetrics patients are not available.
Director of Clinical Laboratories,
University of Vermont Medical Center